Ken Fisher Neurocrine Biosciences Inc Transaction History

Fisher Asset Management, LLC

$243 Billion
Q3 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fisher Asset Management, LLC holds 68,270 shares of NBIX stock, worth $9.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

68,270

Previous 63,340 7.78%

Holding current value

$9.25 Million

Previous $8.72 Million 9.87%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$114.58 - $153.15 $564,879 - $755,029	4,930 Added 7.78%	68,270 $7.86 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $238,950 - $261,464	-1,826 Reduced 2.8%	63,340 $8.72 Million
Q1 2024 May 09, 2024	BUY	$130.4 - $143.74 $644,045 - $709,931	4,939 Added 8.2%	65,166 $8.99 Million
Q4 2023 Mar 05, 2024	BUY	$106.07 - $132.76 $27,153 - $33,986	256 Added 0.43%	60,227 $7.94 Million
Q4 2023 Feb 06, 2024	SELL	$106.07 - $132.76 $196,865 - $246,402	-1,856 Reduced 3.0%	59,971 $7.9 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $16,829 - $20,960	-179 Reduced 0.29%	61,827 $6.96 Million
Q2 2023 Dec 12, 2023	BUY	$89.53 - $104.87 $16,025 - $18,771	179 Added 0.29%	62,006 $5.85 Million
Q2 2023 Aug 08, 2023	SELL	$89.53 - $104.87 $222,123 - $260,182	-2,481 Reduced 3.85%	62,006 $5.85 Million
Q1 2023 Dec 12, 2023	BUY	$94.11 - $123.02 $217,864 - $284,791	2,315 Added 3.74%	64,142 $6.49 Million
Q1 2023 May 01, 2023	BUY	$94.11 - $123.02 $20,610 - $26,941	219 Added 0.34%	64,487 $6.53 Million
Q4 2022 Feb 03, 2023	SELL	$106.72 - $127.06 $90,498 - $107,746	-848 Reduced 1.3%	64,268 $7.68 Million
Q3 2022 Nov 08, 2022	SELL	$92.03 - $107.81 $493,464 - $578,077	-5,362 Reduced 7.61%	65,116 $6.92 Million
Q2 2022 Aug 09, 2022	SELL	$75.79 - $100.07 $316,650 - $418,092	-4,178 Reduced 5.6%	70,478 $6.87 Million
Q1 2022 May 05, 2022	BUY	$72.45 - $94.81 $652 - $853	9 Added 0.01%	74,656 $7 Million
Q4 2021 Feb 02, 2022	BUY	$79.65 - $106.22 $434,331 - $579,217	5,453 Added 7.88%	74,647 $6.36 Million
Q3 2021 Oct 26, 2021	BUY	$86.18 - $99.03 $650,228 - $747,181	7,545 Added 12.24%	69,194 $6.64 Million
Q2 2021 Jul 27, 2021	BUY	$89.43 - $102.27 $310,590 - $355,183	3,473 Added 5.97%	61,649 $6 Million
Q1 2021 Apr 27, 2021	BUY	$87.57 - $119.4 $65,327 - $89,072	746 Added 1.3%	58,176 $5.66 Million
Q4 2020 Jan 29, 2021	SELL	$86.91 - $108.33 $155,655 - $194,019	-1,791 Reduced 3.02%	57,430 $5.51 Million
Q3 2020 Nov 10, 2020	SELL	$96.16 - $135.15 $385,216 - $541,410	-4,006 Reduced 6.34%	59,221 $5.7 Million
Q2 2020 Aug 07, 2020	SELL	$85.09 - $130.36 $114,020 - $174,682	-1,340 Reduced 2.08%	63,227 $7.71 Million
Q1 2020 Apr 28, 2020	SELL	$75.11 - $113.76 $165,842 - $251,182	-2,208 Reduced 3.31%	64,567 $5.59 Million
Q4 2019 Feb 12, 2020	SELL	$86.8 - $118.57 $542,673 - $741,299	-6,252 Reduced 8.56%	66,775 $7.18 Million
Q3 2019 Oct 29, 2019	SELL	$83.82 - $101.5 $116,761 - $141,389	-1,393 Reduced 1.87%	73,027 $6.58 Million
Q2 2019 Jul 30, 2019	BUY	$72.24 - $91.27 $3.41 Million - $4.31 Million	47,257 Added 173.98%	74,420 $6.28 Million
Q1 2019 Apr 22, 2019	SELL	$69.31 - $91.53 $33,060 - $43,659	-477 Reduced 1.73%	27,163 $2.39 Million
Q4 2018 Jan 25, 2019	SELL	$68.32 - $124.36 $34,638 - $63,050	-507 Reduced 1.8%	27,640 $1.97 Million
Q3 2018 Oct 24, 2018	SELL	$98.88 - $125.85 $315,921 - $402,090	-3,195 Reduced 10.19%	28,147 $3.46 Million
Q2 2018 Jul 09, 2018	BUY	$75.3 - $105.99 $1.94 Million - $2.72 Million	25,702 Added 455.71%	31,342 $3.08 Million
Q1 2018 Apr 19, 2018	BUY	$75.88 - $92.43 $46,666 - $56,844	615 Added 12.24%	5,640 $468,000
Q4 2017 Jan 24, 2018	SELL	$58.53 - $77.59 $1,638 - $2,172	-28 Reduced 0.55%	5,025 $390,000
Q3 2017 Oct 17, 2017	BUY	$47.97 - $61.28 $242,392 - $309,647	5,053	5,053 $310,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account